In addition, a recent study has shown the vast majority of MNAC/MLA harbor KRAS/NRAS mutations, inhibiting the RAS/MAPK pathway could potentially be a useful method in the treatment of ovarian MLA.[14] However, further studies will need to be conducted to better understand the clinical characteristics, optimal treatment and prognosis of MLA. This evidence concerns the gene KRAS and microphthalmia with limb anomalies.